{"disease":{"id":"advanced-pancreatic-adenocarcinoma","name":"advanced pancreatic adenocarcinoma"},"drugs":{"marketed":[{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06861088","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Quercis Pharma AG","has_results":false},{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT05149326","title":"KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":408,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06958328","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04423731","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT05524090","title":"PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":223,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT03126435","title":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"SynCore Biotechnology Co., Ltd.","has_results":true},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT04705818","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT07021066","title":"Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT07241663","title":"Surgery for Locally Unresectable Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04821284","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Flemming Forsberg","has_results":false},{"nct_id":"NCT03673137","title":"Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT04481204","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04789486","title":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04172532","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT01585805","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06266143","title":"A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06600906","title":"Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06825546","title":"Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT05737706","title":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT07408505","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT05688215","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03077685","title":"Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT04718701","title":"Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07189195","title":"TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT06399172","title":"OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"OncoSil Medical Limited","has_results":false},{"nct_id":"NCT07269626","title":"PULSAR in Systemic Therapy for Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03767582","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT05078775","title":"Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Faeth Therapeutics","has_results":false},{"nct_id":"NCT02404363","title":"Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02227940","title":"Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07157033","title":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Xerient Pharma","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05498597","title":"AMT-151 in Patients With Selected Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT07114861","title":"The KN510713 Study in Combination With mFOLFIRINOX","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"New Cancer Cure-Bio Co.,Ltd.","has_results":false},{"nct_id":"NCT06472037","title":"AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06405490","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05919238","title":"Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Impact Biotech Ltd","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}